Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 53Brain Neoplasms 51Carcinoma, Non-Small-Cell Lung 49Lung Neoplasms 30Neoplasm Metastasis 29Breast Neoplasms 23Pancreatic Neoplasms 16Melanoma 15Carcinoma, Renal Cell 14Carcinoma, Hepatocellular 13Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Kidney Neoplasms 5Liver Neoplasms 4Glioblastoma 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Spinal Cord Neoplasms 3Sarcoma 3Prostate Cancer Metastatic 3NSCLC 3Meningioma 3Lymphatic Metastasis 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3

Interventions

Nivolumab 2Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2FAPI-46 2olaparib 1lutetium Lu 177 dotatate 1Radiosurgery 1Floxuridine 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Gland Neoplasms × Radiosurgery × 1 year × Clear all
NCT04785287 2026-03-03

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Terminated
13 enrolled
EndocrineGastrointestinalThoracic

Adrenal Gland Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡